Targeting protein-protein interactions (PPIs) remains one of the biggest challenges in drug discovery. Antibodies, while highly specific, are often limited by poor tissue penetration, high production costs, and an inability to access intracellular targets. Small molecules, on the other hand, typically lack the necessary surface area and binding affinity to effectively modulate the large, flat, and hydrophobic interfaces of PPIs, leading to low specificity and off-target effects.

To overcome these limitations, research at Fetse Lab focuses on developing peptide-based modulators that combine the specificity of antibodies with the cell permeability and versatility of small molecules. Using rational design, phage display technology, and computational modeling, we engineer peptides and peptidomimetics capable of selectively disrupting or enhancing PPIs involved in cancer, neurodegenerative diseases, and immune regulation. With AI-driven optimization, our goal is to create next-generation therapeutics that address previously undruggable targets and expand treatment possibilities.